Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.7), the stock would be worth €-0.69 (944% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2 | €0.08 |
0%
|
| Industry Average | 16.7 | €-0.69 |
-944%
|
| Country Average | 6.7 | €-0.28 |
-441%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Gensight Biologics SA
PAR:SIGHT
|
18.1m EUR | -2 | -1.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 18.9 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 18.9 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 16.8 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 30.7 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 15.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 125.8 | 39.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 12.4 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.4 |
| Median | 6.7 |
| 70th Percentile | 12 |
| Max | 2 287.4 |
Other Multiples
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
